Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2021-01-26 Director's Dealing
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
DGAP-DD: Evotec SE english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'DGAP-DD: Evotec SE english' and contains the header 'Directors’ Dealings | 26 January 2021 16:50'. Section 1 identifies the individual as a 'Member of the managing body' (a director/executive). Section 4 details a 'transaction(s)' involving shares. This content directly corresponds to the definition of Director's Dealing, which is classified as 'DIRS'. The document is a direct disclosure, not an announcement of a report.
2021-01-26 English
Report Publication Announcement 2021
Report Publication Announcement Classification · 100% confidence The document is titled "Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements." It explicitly states that it is an announcement regarding the *disclosure* dates and locations for future financial reports (Quarterly/Interim statements). According to Rule 2 (The "MENU VS MEAL" Rule), a short document announcing the publication of a report, rather than containing the report itself, should be classified as a Report Publication Announcement (RPA). The document is short (2085 characters) and serves only to inform about future report releases.
2021-01-19 English
Report Publication Announcement 2021
Report Publication Announcement Classification · 100% confidence The document is titled "Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG". It explicitly states that it is a 'Preliminary announcement' regarding the disclosure dates and locations for future reports, specifically mentioning the 'Annual financial report of the group' and the 'Financial report of the group (half-year/Q2)'. Since the document itself is an announcement about when reports will be published, and not the reports themselves, it fits the definition of a Report Publication Announcement (RPA). The document length is short (2149 chars), supporting the 'MENU VS MEAL' rule.
2021-01-19 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' by a legal entity (Morgan Stanley) in Evotec SE. It specifies changes in the percentage of voting rights attached to shares and instruments, referencing German securities law (WpHG). This content directly aligns with the definition of reporting changes in significant share ownership thresholds, which corresponds to the Major Shareholding Notification category.
2021-01-07 English
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
Regulatory Filings Classification · 95% confidence The document is a press release dated January 7, 2021, announcing that Evotec SE management will be presenting at and attending several upcoming investor conferences in Q1 2021 (J.P. Morgan, Commerzbank, UniCredit Kepler Cheuvreux, BioCapital Europe). This type of announcement, which details management's schedule for engaging with investors at external events, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate action categories (like DIV, CAP, SHA). It is a general corporate communication regarding investor relations activities. Since it is a specific announcement that doesn't match the other defined categories, the most appropriate classification is the general regulatory/corporate announcement fallback, RNS (Regulatory Filings), although it is primarily investor relations focused. Given the options, RNS serves as the best catch-all for non-standard, yet official, corporate news releases.
2021-01-07 English
EVOTEC ACHIEVES MILESTONE IN ITS NEURODEGENERATION COLLABORATION WITH BRISTOL MYERS SQUIBB
Regulatory Filings Classification · 99% confidence The document is a news release dated January 5, 2021, announcing a specific corporate event: Evotec receiving a US$ 6m payment from Bristol Myers Squibb due to the addition of another drug discovery project to their collaboration portfolio. It details a milestone achievement related to their ongoing partnership. This type of announcement, which reports on a specific business development, partnership milestone, or financial event outside of routine periodic reporting (like 10-K or IR), fits best under the general category of a Regulatory Filing or News Announcement, as it is disseminated via DGAP (a service for regulatory announcements). Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific transaction (POS, CAP), the most appropriate general classification for a non-standard, material corporate announcement disseminated via a regulatory service is RNS (Regulatory Filings/Miscellaneous). It is not an ER because it focuses on a partnership milestone payment, not overall period earnings.
2021-01-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.